[ad_1]
BioNTech is working on an improved formula for its vaccine, which will allow it to be transported at room temperature, Ugur Sahin, the company founder, said in an interview with CNN, according to Mediafax.
BioNTech and Pfizer announced that the collaboratively developed vaccine was a success in testing phases, demonstrating 95% efficiency. But the conditions for transporting and storing the vaccine are difficult to meet: the product must be kept at -75 degrees Celsius, 50 degrees colder than any other vaccine currently used in the United States. Government offices, pharmacies, and laboratories do not have freezers that reach such low temperatures.
For this BioNTech has announced that it is working on a variant of the vaccine, which can also be transported at room temperature.
“Since vaccine development has been so rapid, we have not been able to create more stable conditions. We believe that in the second half of 2020 we will have a formula that is comparable to any other vaccine,” said Ugur Sahin.
BioNTech vaccine, 95% efficiency
A final analysis of the Phase 3 study of the COVID vaccine manufactured by Pfizer and BioNTech shows it was 95 percent effective in preventing infections, even in the elderly, and caused no serious safety concerns, the company announced Wednesday.
The studies reported 170 cases of coronavirus infection among the volunteers who took part in the tests. Of these cases, 162 infections occurred in people who received placebo or simple saline vaccines, while eight were in participants who received the same vaccine. This translates into 95 percent efficiency, Pfizer says.
.
[ad_2]
Source link
